Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer.
The actin cytoskeleton is the key cellular machinery responsible for cellular movement. Changes in the organization and distribution of actin and actin binding protein are necessary for several cellular processes such as focal adhesion formation, cell motility and cell invasion. Here we examined differences in cytoskeletal protein distribution, cell morphometry and cell motility of metastatic and non-metastatic cells. Correlations were found between metastatic potential phenotypic properties such as cell motility, cell spreading and cytoskeletal organization in prostate cancer. As a cell progresses from a normal state to a malignant state, it loses its ability to function normally and also become poorly differentiated. Differentiation therapy is concerned with the redirection of malignant cells toward a terminal, non-dividing state using non-cytotoxic agents. Two well acknowledged differentiation agents, retinoic acid (RA) and diflouromethylomithine (DFMO) were examined for their ability to alter cellular phenotypes associated with metastatic potential in rat prostate cancer cell lines. The results of these studies indicate that there are sub-cellular differences between non-metastatic and highly metastatic cells relative to cytoskeletal organization. We also show that treatment of highly metastatic cells with either RA or DFMO significantly alters cell morphology, cell morphometry and motility to states similar to non-metastatic cells.
Donald
C D
CD
Department of Biological Sciences, Clark Atlanta University, GA 30314, USA.
Cooper
C R
CR
Harris-Hooker
S
S
Emmett
N
N
Scanlon
M
M
Cooke
D B
DB
D000199:Actins / Q000032:analysis; D000230:Adenocarcinoma / Q000473:pathology* / Q000556:secondary / Q000648:ultrastructure; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D003599:Cytoskeleton / Q000187:drug effects / Q000648:ultrastructure*; D000518:Eflornithine / Q000494:pharmacology; D008297:Male; D018613:Microscopy, Confocal; D009362:Neoplasm Metastasis; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000648:ultrastructure; D051381:Rats; D011919:Rats, Inbred Strains; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000199:Actins; D000970:Antineoplastic Agents; D014212:Tretinoin; D000518:Eflornithine